Teacher’s day special
*********
We wish everyone a happy Teacher’s day. On this special occasion, we are happy to announce that ideas posted today (05/September/2016) will be available to the use of Scientists/Professors/Physicians/Researchers for free.
So, there will be no terms and conditions for the ideas posted today (05/September/2016). Each idea posted will be served first come, first served basis.Write to info@genomediscovery.org for more details about the idea posted.
Dr L Boominathan PhD
CEO & CSO, GBMD.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Undisclosed information: How MiR-7-3p increases the expression of tumor suppressor AIM2.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
A recent study from the Department of Immunology, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA shows that: “Critical Role for the DNA Sensor AIM2 in Stem Cell Proliferation and Cancer”. This study was published in the 17 June 2015 issue of the journal “Cell” (the number 1 research journal in “General biology” with an Impact factor of 33.16) by Prof. Thirumala Devi Kanneganti, Si Ming Man and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: MiRNA therapy for Intestinal cancer: MiRNA-7-3p increases the expression of DNA Sensor AIM2 and inhibits expansion of tumor-initiating intestinal stem cell population via up regulation of its target gene
Significance:
Given that (1) more than 1 million people every year worldwide are affected by Intestinal cancer; (2) the number of deaths has had increased from 490,000 in 1990 to 715,000 in 2010; (3) Intestinal cancer is the second and third most frequent cause of cancer in women and men, respectively; (4) Intestinal cancer is more common in developed countries than in developing countries; and (5) the global economic cost spent for Intestinal cancer treatment is enormous, there is an urgent need to find: (1) a cheaper alternative to the existing expensive drugs; and (2) a side-effect-free drug.
A number of studies suggests that immune sensor Absent in Melanoma 2 (AIM2) is mutated in colorectal cancer. However, the significance of which is far from clear. Prof. Thirumala Devi Kanneganti’s research team has recently shown that AIM2 protects against colorectal cancer via inhibition of tumor-initiating intestinal stem cell proliferation.
Figure 1 MiR-7-3p inhibits uncontrolled proliferation of tumor-initiating intestinal stem cells and the progression of colorectal cancer via up regulation of AIM2 (Click to enlarge picture)
This study suggests that MiRNA-7-3p, by decreasing the expression of its target gene, it may increase the expression of tumor suppressor AIM2. Thereby, it may: (1) inhibit uncontrolled proliferation of tumor-initiating intestinal stem cells; (2) decrease the population of dysbiotic gut microbiota; and (3) prevent colorectal cancer. Thus, pharmacological formulations encompassing “MiRNA-7-3p activators“ may be used to inhibit the progression of colorectal cancer.
* Research cooperation
Citation: Boominathan, L., MiRNA therapy for Intestinal cancer: MiRNA-7-3p increases the expression of DNA Sensor AIM2 and inhibits expansion of tumor-initiating intestinal stem cell population via up regulation of its target gene, 5/September/2016, 6.48 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Web: http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org